| Novel oral anticoagulants in development: dabigatran, rivaroxaban, and apixaban. | |
| | |
MedLine Citation:
|
PMID: 20535013 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism, is a cause of significant mortality and morbidity. For several decades, anticoagulant options for the treatment and prevention of thrombosis have been limited mainly to agents such as unfractionated heparin and oral vitamin K antagonists, such as warfarin. Although these therapies have proven benefits, they also have important limitations that result in their underuse in routine clinical practice. A variety of novel anticoagulants with improved pharmacologic and clinical profiles are in development, offering benefits over traditional therapies. Specifically, progress has been made in the development of small molecule factor Xa inhibitors and thrombin inhibitors. With their potentially consistent and predictable clinical profile, oral formulation, and decreased need for coagulation monitoring, these new agents will likely increase the use and duration of anticoagulation treatment in thromboembolic disorders and reduce the burden associated with long-term management. |
| | |
Authors:
|
Maryam Sattari; David T Lowenthal |
Related Documents
:
|
6492383 - Antithromboembolic treatment after cardiac valve replacement. 23291703 - Does electroconvulsive therapy cause epilepsy? 7890893 - Prevention of relapse in patients with chronic non-a, non-b/c hepatitis who respond to ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: American journal of therapeutics Volume: 18 ISSN: 1536-3686 ISO Abbreviation: Am J Ther Publication Date: 2011 Jul |
Date Detail:
|
Created Date: 2011-07-11 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9441347 Medline TA: Am J Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 332-8 Citation Subset: IM |
Affiliation:
|
1Department of Internal Medicine, University of Florida, College of Medicine, Gainesville, FL; and 2Department of Internal Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Practitioners and nondrug treatment of hypertension, effects of participating in a survey.
Next Document: Combination Therapy for Managing Difficult-to-Treat Patients With Stage 2 Hypertension: Focus on Val...